DR. DAVID ALAN MCCARRON
Osteopathic Medicine at 9 Ave, Portland, OR
License number
Oregon MD10925
Category
Osteopathic Medicine
Type
Nephrology
Address
Address
120 NW 9Th Ave SUITE 206, Portland, OR 97209
Phone
(503) 957-0511
Personal information
See more information about DAVID ALAN MCCARRON at radaris.comName
Address
Phone
2605 SW Buena Vista Pl, Portland, OR 97201
3181 Sam Jackson Park Rd, Portland, OR 97239
2605 Buena Vista Dr, Portland, OR 97201
Portland, OR
Professional information
M.d.
Position:
Adjunct Professor at U.C. Davis, Department of Nutrition, CEO at The McCarron Group
Location:
Portland, Oregon Area
Industry:
Hospital & Health Care
Work:
U.C. Davis, Department of Nutrition
since 2001
-
Adjunct Professor
The McCarron Group
since Jan 1998
-
CEO
Academic Network
Jan 2001 - Sep 2008
-
President
Oregon Health and Sciences University
Jul 1977 - Jan 2001
-
Professor of Medicine
Education:
Tufts University School of Medicine 1974 - 1977
Fellowship, Nephrology Fellowship Case Western Reserve University School of Medicine 1971 - 1973
University of Pennsylvania School of Medicine 1967 - 1971
M.D., Medicine Williams College 1963 - 1967
BA, Chemistry (Honors)
Fellowship, Nephrology Fellowship Case Western Reserve University School of Medicine 1971 - 1973
University of Pennsylvania School of Medicine 1967 - 1971
M.D., Medicine Williams College 1963 - 1967
BA, Chemistry (Honors)
Skills:
Nutrition, Research, Healthcare
Honor & Awards:
Fellow American College of Physicians
Fellow American Heart Association, Council on High Blood Pressure Research
American Physiological Society
American Society of Clinical Investigation
2004 International Award in Nutrition Research
Use Of Retinoids To Treat High Blood Pressure And Other Cardiovascular Disease
US Patent:
6437003, Aug 20, 2002
Filed:
Jun 3, 1999
Appl. No.:
09/325241
Inventors:
Jean-Baptiste Roullet - Portland OR 97221
David A McCarron - Portland OR 97201
David A McCarron - Portland OR 97201
International Classification:
A61K 3107
US Classification:
514725
Abstract:
This invention provides methods of treating a disease in a mammal where the disease is characterized by a symptom ameliorated by inhibition of cellular calcium influx. The methods involve administering to the mammal an effective amount of a retinoid and a pharmacologically acceptable excipient.
Use Of Retinoids To Treat High Blood Pressure And Other Cardiovascular Disease
US Patent:
2003000, Jan 9, 2003
Filed:
Aug 20, 2002
Appl. No.:
10/223970
Inventors:
Jean-Baptiste Roullet - Portland OR, US
David McCarron - Portland OR, US
David McCarron - Portland OR, US
International Classification:
A61K031/203, A61K031/07
US Classification:
514/559000, 514/725000
Abstract:
This invention provides methods of treating a disease in a mammal where the disease is characterized by a symptom ameliorated by inhibition of cellular calcium influx. The methods involve administering to the mammal an effective amount of a retinoid and a pharmacologically acceptable excipient.
Use Of Retinoids To Treat High Blood Pressure And Other Cardiovascular Disease
US Patent:
2008021, Sep 4, 2008
Filed:
Oct 31, 2007
Appl. No.:
11/932063
Inventors:
Jean-Baptiste Roullet - Portland OR, US
David A. McCarron - Portland OR, US
David A. McCarron - Portland OR, US
Assignee:
Oregon Health and Sciences University - Portland OR
International Classification:
A61K 31/203, A61K 31/07, A61P 3/04, A61P 25/28, A61P 9/12, C12N 5/06
US Classification:
514559, 514725, 435375
Abstract:
This invention provides methods of treating a disease in a mammal where the disease is characterized by a symptom ameliorated by inhibition of cellular calcium influx. The methods involve administering to the mammal an effective amount of a retinoid and a pharmacologically acceptable excipient.
Dr. David A Mccarron - MD (Doctor of Medicine)
Hospitals:
ACADEMIC NETWORK CENTER
120 NW 9Th Ave SUITE 216, Portland 97209
ACADEMIC NETWORK CENTER
120 NW 9Th Ave SUITE 216, Portland 97209
120 NW 9Th Ave SUITE 216, Portland 97209
ACADEMIC NETWORK CENTER
120 NW 9Th Ave SUITE 216, Portland 97209
Education:
Medical Schools
Perelman School of Medicine University of Pennsylvania
Perelman School of Medicine University of Pennsylvania
David Alan McCarron, Portland OR
Specialties:
Nephrologist
Address:
120 Nw 9Th Ave, Portland, OR 97209
Method For Determining Diet Program Effectiveness
US Patent:
5639471, Jun 17, 1997
Filed:
Jun 6, 1995
Appl. No.:
8/469516
Inventors:
Allen Chait - Seattle WA
Dan Hatton - Portland OR
R. Brian Haynes - Dundas, CA
Chor San Heng Khoo - Mt. Laurel NJ
Penny Kris-Etherton - State College PA
R. David C. Macnair - King of Prussia PA
David McCarron - Portland OR
Jill Metz - Portland OR
Suzanne Oparil - Birmingham AL
Xavier Pi-Sunyer - New York NY
Larry Resnick - West Bloomfield MI
Judith S. Stern - Lafayette CA
Paula J. Ziegler - Cherry Hill NJ
Dan Hatton - Portland OR
R. Brian Haynes - Dundas, CA
Chor San Heng Khoo - Mt. Laurel NJ
Penny Kris-Etherton - State College PA
R. David C. Macnair - King of Prussia PA
David McCarron - Portland OR
Jill Metz - Portland OR
Suzanne Oparil - Birmingham AL
Xavier Pi-Sunyer - New York NY
Larry Resnick - West Bloomfield MI
Judith S. Stern - Lafayette CA
Paula J. Ziegler - Cherry Hill NJ
Assignee:
Campbell Soup Company - Camden NJ
International Classification:
A61K 4700
US Classification:
424439
Abstract:
The invention is a method for determining the effectiveness of a diet program for administration to a patient having at least one diet-responsive condition. The method includes the steps of selecting a plurality of patients, each having at least one diet-responsive condition; identifying at least one quantifiable indicator of each of the diet-responsive conditions and measuring the at least one indicator for each of the patient during a four week baseline period; and monitoring each of the patients during the baseline period to determine a baseline quality of life. The plurality of patient are divided randomly between a first group and a second group. The diet program is administered to each of the patients in the first group during a ten week intervention period and each of the patient in the second group is maintained on a control diet with known beneficial effects on the at least one diet-responsive condition during the intervention period. The at least one indicator of each of the conditions is monitored for each of the patient after the intervention period.